Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke

Curr Drug Targets CNS Neurol Disord. 2005 Apr;4(2):119-20. doi: 10.2174/1568007053544165.

Abstract

Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY x 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Aged
  • Benzopyrans / administration & dosage*
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / etiology
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Humans
  • Neuroprotective Agents / administration & dosage*
  • Serotonin Receptor Agonists / administration & dosage*
  • Stroke / complications
  • Stroke / drug therapy*
  • Thiazoles / administration & dosage*
  • Treatment Outcome

Substances

  • Benzopyrans
  • Neuroprotective Agents
  • Serotonin Receptor Agonists
  • Thiazoles
  • repinotan hydrochloride